Editorial Commentary
Single nucleotide polymorphisms in angiogenesis-related genes and outcomes from antiangiogenic therapies in renal cell carcinoma: really a step towards personalized oncology, or not at all?
Abstract
By definition, single nucleotide polymorphisms (SNPs) are loci with alleles that differ at a single base level, with the rarer allele having a frequency of at least 1% in a random set of individuals within a given population (1).